Clinical Trials for Mesothelioma Patients: Cisplatin, Pemetrexed and Bevaiczumab
Read about a current clinical trial being conducted to study the effects of Cisplatin, Pemetrexed and Bevacizumab for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
Purpose: To estimate the time to progression of cancer in patients with previously untreated mesothelioma receiving cisplatin, pemetrexed and bevacizumab.
Requisite Conditions: Mesothelioma
Intervention: Drugs: Cisplatin, Pemetrexed and Bevacizumab
Study Phase, Type and Design: Phase II Interventional Study; Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: A Phase II Trial of Cisplatin, Pemetrexed and Bevacizumab in Untreated Malignant Mesothelioma
Primary Outcome Measures:
• progression free survival
Secondary Outcome Measures:
• response rate
• overall survival
Recruitment Information:
Recruitment Status: Recruiting
Enrollment: 65
Study Start Date: February 2006
Courtesy of ClinicalTrials.gov.
Other helpful links:
Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney



Clinical drug study criteria of pemetrexed on mesothelioma patients